PMS55 RHEUMATOLOGIST INVOLVEMENT IN CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS
Trivedi DN, Kreilick C, Rosenblatt LC Bristol-Myers Squibb, Plainsboro, NJ, USA OBJECTIVES: To determine physician specialties involved in rheumatoid arthritis (RA) diagnosis and follow-up care. METHODS: A retrospective analysis was performed using PharMetrics" claims database. Patients newly diagnosed with RA (no RA diagnosis claim in prior 12 months) were identifi ed from April 1, 2005, to June 30, 2006, and were followed for 1 year. Patients were required to have at least one additional RA diagnosis claim during the follow-up period and had to be continuously eligible 12 months before and after initial diagnosis date. Outcomes of interest were a) specialty of diagnosing physician b) percentage of patients receiving follow-up care by a rheumatologist versus other specialties. RESULTS: Of newly diagnosed RA patients (N 13,633), 34% were diagnosed by a rheumatologist, 13% by general/ family practice (GP), 13% by internal medicine (IM), and 30% by other specialties (11% were unknown). Of those diagnosed by a rheumatologist, 94% continued receiving rheumatologist care. Of those diagnosed by a GP, 57% continued to receive care from GP and 13% received care from other specialty; of those diagnosed by IM, 65% continued to receive care from IM and 8% received care from other specialty. Approximately 26% of those diagnosed by GP or IM received follow-up care from a rheumatologist. Irrespective of diagnosing physician specialty, the majority of patients (52%) were not followed up by a rheumatologist. CONCLUSIONS: This study demonstrates that the majority of RA patients are not diagnosed or followed by a rheumatologist. Future studies need to assess whether confi rmation of RA diagnosis and follow-up by a rheumatologist, who has extensive training and experience in autoimmune disease, has an impact on patient outcomes.
PMS56 PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING
Carter C 1 , Tang B g 1 , Changolkar A 2 , McKenzie RS 1 , Piech CT 1 1 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2 SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA OBJECTIVES: To examine pharmacy refi ll patterns of etanercept (ETA) and adalimumab (ADA) in the treatment of rheumatoid arthritis (RA) in a managed care population. METHODS: Medical and pharmacy claims (January 1, 2000-December 31, 2006) from a large managed care database were evaluated. Claims for all patients aged 18 years meeting the following criteria were included: two diagnosis codes for RA, no pharmacy or medical history of any biologic use for 6 months prior to anti-TNF agent index date, anti-TNF agent index date occurring on or after the fi rst RA diagnosis date, and 365 persistence days. Patients were excluded if they had a diagnosis of ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, or ulcerative colitis at anytime. Refi ll patterns were examined by calculating the mean time (days) between each pharmacy refi ll using NDC codes (actual refi ll days) compared to the mean days supplied on the claims (recommended refi ll days). Results were reported for the fi rst year following anti-TNF agent initiation. RESULTS: A total of 1239 RA patients newly starting an anti-TNF agent were included (ETA 902, ADA 337). ETA patients were slightly younger than ADA patients (ETA 48.8 years, ADA 49.2 years, p 0.0001). There was no signifi cant gender difference between the two groups (ETA 77% female, ADA 75% female, p 0.29). Mean recommended days supplied were 32 and 34 days for ETA and ADA, respectively. Mean days between actual ETA pharmacy refi lls were longer than recommended for 30% of the refi ll periods. Mean days between actual ADA pharmacy refi lls were longer than recommended for 28% of the refi ll periods. CONCLUSIONS: Approximately onethird of the actual pharmacy fi lls for ETA and ADA had a longer time to patient refi ll compared to the recommended days supply, which may indicate noncompliance.
PMS57 PRIMARY CARE VISITS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING INTRAVENOUS VERSUS SUBCUTAENOUS BIOLOGICS: A RETROSPECTIVE CLAIMS DATABASE STUDY
Rosenblatt LC, Oza D Bristol-Myers Squibb, Plainsboro, NJ, USA OBJECTIVES: To determine whether patients diagnosed with rheumatoid arthritis (RA) receiving intravenous (IV) biologics are more likely to visit a primary care physician (PCP) than patients receiving subcutaneous (SC) biologics for their RA treatment. METHODS: A retrospective claims analysis was performed using PharMetrics PatientCentric Database. RA patients receiving biologic therapy were identifi ed from January 2003 to December 2006 and followed for at least 12 months after their fi rst prescription for IV or SC biologic (defi ned as index date). Logistic regression analysis predicting PCP visits was conducted, controlling for covariates, such as age, gender, region, payer type, provider type, Charlson Comorbidity Index, and specifi c RA-related comorbidities found to be signifi cant in univariate analysis. RESULTS: There were 1289 IV and 2543 SC patients included in the study. There were 73% females in the IV group vs. 71% in the SC group. Mean age was 58 years in the IV group and 53 years in SC group. The odds of having a PCP visit during follow-up period were 1.22 (95% CI-1.03, 1.44) times higher in the IV group as compared to the SC group, when controlling for covariates such as age and comorbidities. CONCLUSIONS: RA patients receiving IV biologics are more likely to maintain PCP visits compared to patients receiving SC biologics. Future study needs to determine if more frequent interaction with the health care system can lead to better general health care and the likelihood of receiving holistic care in patients receiving IV biologics.
PMS58
FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT Nasonov E 1 , Le Lay K 2 , Soldatov D 3 , Taieb C 2 1 Rheumatology Institute-Russian Federation, Moscou, Russia, 2 Pierre Fabre, Boulogne, France, 3 Pierre Fabre Laboratories, Moscou, Russia OBJECTIVES: Fibromyalgia syndrome (FMS) is an under-diagnosed disorder, of unknown etiology, which affects over 5% of patients in general medical practice; to describe Russian rheumatologists' disease management of fi bromyalgia patients.
METHODS:
The questionnaire was sent to a random sample of Russian practitioners, who were answering the same questionnaire as that used by French practitioners in 2003. RESULTS: Seventy-seven of the practitioners claimed that they prescribed a medical treatment to their patients suffering from fi bromyalgia: 40% prescribed antalgics, 40% prescribed tricyclic antidepressants, 29% serotoninergic anti-depressants, 30% hypnotics/sedatives, 8 % homeopathic treatments and a little over 1% morphine derivatives. 67% claimed that they prescribed extra treatments for their patients suffering from fi bromyalgia: 23% prescribed antalgics, 20% prescribed tricyclic antidepressants, 17% serotoninergic antidepressants, 24% hypnotics/sedatives, 9% homeopathic treatments and less than 1% morphine derivatives. 82.6 % recommended or prescribed other treatments to their fi bromyalgic patients, namely: 36% acupuncture, 56% physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% osteopathy and 38% relaxation techniques. 91.8% of the doctors advised regular physical exercise such as swimming and walking (71.9% and 65.6% respectively), with cycling being the activity least often advised, by 12.9% of the doctors. CONCLUSIONS: Treatment for fi bromyalgia must be multidisciplinary and multifactorial, its main objective being relieving the patient of their symptoms and allowing them to return to their professional and leisure activities -to which treatment of the condition by Russian practitioners is a testimony.
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META-ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
Hawkins NS 1 , Huntley A 2 , Eaton J 2 1 Oxford Outcomes (UK), Oxford, UK, 2 Oxford Outcomes (UK), Oxford, Oxfordshire, UK OBJECTIVES: To assess the comparative effi cacy of biologics for the treatment of moderate to severe psoriasis. METHODS: A systematic literature review was conducted to identify all randomized, controlled trials (until October 2008) evaluating the effi cacy of approved biologics (adalimumab, efalizumab, etanercept, and infl iximab) for the treatment of moderate to severe psoriasis. As regulatory approval of ustekinumab in this indication is anticipated shortly, three Phase 3 trials of ustekinumab were also included in this review. A network meta-analysis (NMA) conducted on
